NDAINTRAVENOUSSOLUTION
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBY-FILL (Rubidium Rb 82) is an intravenous radiopharmaceutical diagnostic agent approved in 2016. It is used for myocardial perfusion imaging to assess coronary artery disease and cardiac viability in patients with suspected or known ischemic heart disease. The drug works as a positron-emitting tracer that accumulates in perfused myocardium, enabling PET imaging.
Peak
Product is in peak commercialization phase with moderate competitive pressure (30%), indicating stable team size and established market presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RUBY-FILL offers limited publicly visible job openings (0 linked), reflecting its mature market status and specialized diagnostic focus. Careers in this space emphasize deep technical knowledge of cardiac imaging protocols, hospital relationships, and healthcare provider partnerships rather than high-volume commercial expansion.
Diagnostic Imaging SpecialistMedical Affairs Manager
Worked on RUBY-FILL at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.